Evaluation of Drug Utilization in the Infected Patients with ESBLs Produced by Enterobacteriaceaein

Xueting YANG; Huifeng ZHANG

doi:10.12259/j.issn.2095-610X.S20220621

Volume 43 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(6): 74-78

Xueting YANG, Huifeng ZHANG. Evaluation of Drug Utilization in the Infected Patients with ESBLs Produced by Enterobacteriaceaein[J]. Journal of Kunming Medical University, 2022, 43(6): 74-78. doi: 10.12259/j.issn.2095-610X.S20220621

Citation:

Xueting YANG, Huifeng ZHANG. Evaluation of Drug Utilization in the Infected Patients with ESBLs Produced by Enterobacteriaceaein[J]. Journal of Kunming Medical University, 2022, 43(6): 74-78. doi: 10.12259/j.issn.2095-610X.S20220621

Citation:

PDF( 588 KB)

Evaluation of Drug Utilization in the Infected Patients with ESBLs Produced by Enterobacteriaceaein

doi: 10.12259/j.issn.2095-610X.S20220621

Xueting YANG,
Huifeng ZHANG^,

Dept. of Pharmacy，The First People’s Hospital of Yunnan Province/The Affiliated Hospital of Kunming University of Science and Technology，Kunming Yunnan 650032，China

Received Date: 2022-03-18
Available Online: 2022-06-07
Publish Date: 2022-06-30

Abstract

Abstract

Objective To evaluate the rationality of antibiotics utilization in the infected patients with ESBLs produced by Enterobacteriaceaein one hospital． Methods The methods of drug utilization review（DUR） and drug utilization evaluation（DUE） were used to analyze the drug utilization, drug use index（DUI） , selection of antibacterials, medicine regimen and therapeutic outcome in 135 patients with ESBLs produced by Enterobacteriaceaein in the hospital from January 2017 to June 2017. Results The DUR method involved 16 kinds of antibiotics． Among them, 8 kinds were with DUI below 1, 5 kinds with DUI equal to 1, and 3 kinds with DUI above 1．The drugs with top five DDDs were cefmenoxime, cefoperazone sulbactam, levofloxacin and ceftriaxone. 100%; yet monitoring of PCT, liver function and adverse drug reactions had lower qualified rate. DUE criteria showed that qualified rate adverse drug reactions was 100%; yet the right antibiotics were selected for mild and moderate infection that it produced ESBLs risk factors（28.87%）, and the de-escalation treatmen was right（30%）. Conclusions A more comprehensive evaluation of drug utilization in patients with ESBLs produced by Enterobacteriaceaein can be achieved using DUR combined with DUE methods. The layering use of antibiotics and rational selection medicine regimen for the patients within the infected patients with ESBLs produced by Enterobacteriaceaein in the hospital still needs to be strengthened．
- ESBLs produced by Enterobacteriaceaein,
- Antibiotics,
- Drug utilization review,
- Drug utilization evaluation,
- Drug utilization index

FullText(HTML)

References(15)

References

[1]	Stewart A G,Price E P,Schabacker K,et al. Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland,Australia[J]. Antimicrobial Agents and Chemotherapy,2021,65(6):1-13.
[2]	Onduru O G,Mkakosya R S,Aboud S,et al. Genetic Determinants of Resistance among ESBL-Producing Enterobacteriaceae in Community and Hospital Settings in East,Central,and Southern Africa:A Systematic Review and Meta-Analysis of Prevalence[J]. Canadian Journal of Infectious Diseases and Medical Microbiology,2021,21:1-9.
[3]	Ishiwada N,Fujimaki K,Matsumoto T,et al. Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy,the Japanese Association for Infectious Diseases,and the Japanese Society for Clinical Microbiology in 2017:General overview of pathogenic antimicrobial susceptibility[J]. J Infect Chemother,2021,27(2):139-150. doi: 10.1016/j.jiac.2020.11.020
[4]	Liang Y,Qiu L,Zheng X,et al. Trend in Antimicrobial Resistance of Staphylococcus aureus:Results from the China Antimicrobial Surveillance Network (CHINET) in the Last 15-Year-Period Reports (2005-2019)[J]. Infection and Drug Resistance,2021,14:2179-2181. doi: 10.2147/IDR.S318005
[5]	周华,李光辉,陈柏义,等. 中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志,2014,94(24):1847-1856. doi: 10.3760/cma.j.issn.0376-2491.2014.24.003
[6]	《抗菌药物临床应用指导原则》修订工作组. 抗菌药物临床应用指导原则. （2015 年版）[M]. 北京: 人民卫生出版社. 2015: 1-184.
[7]	Heireman L,Vandendriessche S,Coorevits L,et al. Effects of cascade reporting of susceptibility profiles for Enterobacterales on broad-spectrum antibiotics use and resistance[J]. Eur J Hosp Pharm.,2022,29(2):79-83. doi: 10.1136/ejhpharm-2021-002951
[8]	ShettyY C,Manjesh P S,Churiwala W,et al. Drug use evaluation of cephalosporins in a tertiary care hospital[J]. Perspect Clin Res.,2022,13(1):38-42. doi: 10.4103/picr.PICR_29_20
[9]	Bientinesi R,Murri R,Sacco E,et al. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis[J]. Expert Opin Pharmacother,2020,21(6):637-644. doi: 10.1080/14656566.2020.1720647
[10]	李维特,张捷. 耐碳青霉烯肠杆菌科细菌耐药机制的研究进展[J]. 中华医院感染学杂志,2017,27(3):714-716.
[11]	张功武. 我院肠杆菌科细菌对碳青霉烯类抗菌药物的耐药性分析[J]. 中国药房,2017,28(5):614-617. doi: 10.6039/j.issn.1001-0408.2017.05.10
[12]	刘明涛,常刚,李凯述. 万古霉素分别联合三种抗菌药物对异质性万古霉素中介金黄色葡萄球菌耐药突变选择窗的影响[J]. 中华医院感染学杂志,2017,27(14):3147-3157.
[13]	朱裕林,桑冉,张永,等. 注射用左氧氟沙星的药物利用评价[J]. 中国医院药学杂志,中国医院药学杂志,2017,37(17):1721-1724.
[14]	De W S,Wauters J,Meersseman W,et al. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock:a randomised controlled trial[J]. International Journal of Antimicrobial Agents,2018,51(4):562-570. doi: 10.1016/j.ijantimicag.2017.11.009
[15]	林金华,周艳芳,凌丽燕. 头孢曲松钠与不同浓度含钙溶液混合后钙离子浓度的变化研究[J]. 中国药房,2013,24(9):790-793. doi: 10.6039/j.issn.1001-0408.2013.09.08

Relative Articles(20)

Relative Articles

[1]	Xuemei CHEN, Pin GUO, Liufang CHUAN, Zi WANG, Xuejiao LI, Wenji HE. Evaluation of Cardiac Toxicity of Anthracyclines in Children with Acute Leukemia Based on Tei Index. Journal of Kunming Medical University, 2024, 45(2): 117-122. doi: 10.12259/j.issn.2095-610X.S20240216
[2]	Xing LIU, Weixian LI, Yan WU, Xuejiao WU, Xiaodie YAO, Jie CHEN, Lingjun SHEN, Hao FAN. Efficacy and Safety of Jingangteng Capsules Combined with Antimicrobial Drugs in the Treatment of Chronic Pelvic Inflammatory Disease: A Meta-analysis. Journal of Kunming Medical University, 2024, 45(4): 81-91. doi: 10.12259/j.issn.2095-610X.S20240412
[3]	Jianming SUN, Yuan LI, Qin SU. The Clinical Features and Antibiotic Selection in Children with Acute Leukemia Complicated by Bloodstream Infections from Multidrug-Resistant Bacteria. Journal of Kunming Medical University, 2024, 45(11): 1-7.
[4]	Xuelin ZHANG, Lu LIU, Yanzhi CHEN, Caijun ZHA, Yanli LI. The Distribution and Drug Resistance of Pathogenic Bacteria in Respiratory Tract Infections in Children from 2019 to 2022. Journal of Kunming Medical University, 2024, 45(1): 149-155. doi: 10.12259/j.issn.2095-610X.S20240125
[5]	Jinyi GU, Deyao DENG, Wenli YUAN, Qiuping YANG, Jianmei SONG, Yanjun SHEN, Yuanyuan GUO, Hongyun XU. Clinical Distribution and Drug Resistance Analysis of Acineto Bacterbaumannii from 2014 to 2020. Journal of Kunming Medical University, 2022, 43(5): 83-87. doi: 10.12259/j.issn.2095-610X.S20220504
[6]	Pu-mei CUI, Tai-fang CHEN, Chao CHEN, Yong-mei LIANG, Yue XU. Correlation Analysis of Antimicrobial Use and Common Bacterial Resistance in a Hospital in Yunnan From 2016 to 2019. Journal of Kunming Medical University, 2021, 42(11): 140-147. doi: 10.12259/j.issn.2095-610X.S20211127
[7]	Fu Yan , Li Xin Yi , Yuan Yong , Wang Wei Hua . . Journal of Kunming Medical University, 2019, 40(06): 121-124.
[8]	Cheng Si Gen , Luo Zhi Gang , Liu De Hua , Yang Shu . 幽门螺杆菌清除治疗中甲硝唑、克拉霉素、阿莫西林的耐药性. Journal of Kunming Medical University, 2018, 39(04): 104-108.
[9]	Mao Jian , Ren Yu Ji , Dan Bin , Shao Tian Bo . The Distribution and Drug-resistance of Gram-negative Bacilli among Blood Stream Infection in Yunnan Province of China during 2012～2014. Journal of Kunming Medical University, 2016, 37(12): 24-28.
[10]	Zhao Xiao Li . . Journal of Kunming Medical University,
[11]	Fu Yuan Chun . . Journal of Kunming Medical University,
[12]	Xing Wen Zhong . . Journal of Kunming Medical University,
[13]	Zhu Yan Ping . . Journal of Kunming Medical University,
[14]	Li Chong Yang . . Journal of Kunming Medical University,
[15]	Qi Yan Wei . 云南省HIV/AIDS患者下呼吸道感染病原菌分布及耐药分析. Journal of Kunming Medical University,
[16]	Sun Jian Ming . . Journal of Kunming Medical University,
[17]	Mao Jian . . Journal of Kunming Medical University,
[18]	Hua Peng . . Journal of Kunming Medical University,
[19]	Chen Jin . . Journal of Kunming Medical University,
[20]	Zhou Shi Qiao . . Journal of Kunming Medical University,